Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting
Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting https://www.lysogene.com/wp-content/themes/crocal/images/empty/thumbnail.jpg 150 150 Lysogene https://www.lysogene.com/wp-content/themes/crocal/images/empty/thumbnail.jpg• Promising efficacy data in young patients with persistent increase or stabilization in 3 main…